Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GRCE Grace Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: GRCE
Price (delayed)
$3.04
Market cap
$42.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$19.91M
Highlights
The EPS rose by 41% year-on-year and by 32% since the previous quarter
The company's equity rose by 28% QoQ and by 8% YoY
Grace Therapeutics's quick ratio has surged by 100% QoQ but it has decreased by 18% YoY
Key stats
What are the main financial stats of GRCE
Market
Valuations
Earnings
Shares outstanding
13.83M
Market cap
$42.04M
Enterprise value
$19.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.68M
Net income
-$9.57M
EBIT
-$12.77M
EBITDA
-$12.76M
Free cash flow
-$14.9M
Per share
Balance sheet
Liquidity
EPS
-$0.79
EPS diluted
-$0.79
Free cash flow per share
-$1.23
Book value per share
$6.57
Revenue per share
$0
TBVPS
$1.88
Total assets
$71.99M
Total liabilities
$5.38M
Debt
$0
Equity
$66.61M
Working capital
$20.78M
Debt to equity
0
Current ratio
11.77
Quick ratio
11.53
Net debt/EBITDA
1.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-14.3%
Return on equity
-16.3%
Return on invested capital
N/A
Return on capital employed
-18.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GRCE stock price
How has the Grace Therapeutics stock price performed over time
Intraday
1.33%
1 week
2.7%
1 month
2.36%
1 year
6.67%
YTD
-18.72%
QTD
2.36%
Financial performance
How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.68M
Net income
-$9.57M
Gross margin
N/A
Net margin
N/A
GRCE's operating income is down by 30% year-on-year
Grace Therapeutics's net income has increased by 28% from the previous quarter and by 26% YoY
Price vs fundamentals
How does GRCE's price correlate with its fundamentals
Growth
What is Grace Therapeutics's growth rate over time
Valuation
What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 41% year-on-year and by 32% since the previous quarter
The stock's P/B is 34% below its 5-year quarterly average of 0.7 and 8% below its last 4 quarters average of 0.5
The company's equity rose by 28% QoQ and by 8% YoY
Efficiency
How efficient is Grace Therapeutics business performance
The ROE has grown by 30% from the previous quarter and by 19% YoY
The ROA has grown by 28% from the previous quarter and by 16% YoY
Dividends
What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GRCE.
Financial health
How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has surged by 100% QoQ but it has decreased by 18% YoY
The company's current ratio has surged by 94% QoQ but it fell by 17% YoY
The debt is 100% lower than the equity
The company's equity rose by 28% QoQ and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.